KSPHF:OTCMKTS
Kissei Pharmaceutical Co Ltd
US$24,50
0,00%
(0,00) 1D
1 ຕ.ລ., 10 ໂມງ 21 ນາທີ 43 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KSPHF...
Mkt. cap
172,67 ຕື້
Avg. vol.
20,00
Volume
0,00
52-wk high
US$31,90
52-wk low
US$24,50
Beta
13,94
Shares outstanding
46,54 ລ້ານ
No. of employees
2 ພັນ
Mkt. cap
172,67 ຕື້
Avg. vol.
20,00
Volume
0,00
52-wk high
US$31,90
52-wk low
US$24,50
Beta
13,94
Shares outstanding
46,54 ລ້ານ
No. of employees
2 ພັນ
News stories
From web sources and news partners
TradingView
·
1 ຊົ່ວໂມງກ່ອນ
Retension Pharmaceuticals, Clinical-Stage Developer of Hypertension Therapies, Files for Nasdaq Capital Market IPO
TheStreet Pro
·
21 ນາທີກ່ອນ
A Broad Friday Rally Takes the S&P 500 Just Below Record Highs
Yahoo Finance
·
1 ຊົ່ວໂມງກ່ອນ
Ruanyun Edai Technology Inc. Receives Nasdaq Minimum Bid Price Deficiency Notice
Nasdaq
·
9 ຊົ່ວໂມງກ່ອນ
WISeSat.Space Holdings Corp. Rings the Opening Bell
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 ພັນ
Founded9 ສ.ຫ. 1946
HeadquartersMatsumoto, Nagano, ຍີ່ປຸ່ນ
SectorPharmaceutical industry
Websitekissei.co.jp